Encompass Health Corp EHC is the sector leader in the rehab and the home health sectors, according to Credit Suisse.
The Analyst
Credit Suisse's A.J. Rice initiated coverage of Encompass Health Corp with an Outperform rating and $58 price target.
The Thesis
The company has a growing rehab and home health business, Rice said in a Wednesday note. (See the analyst's track record here.)
Encompass Health Corp has 22 percent of all inpatient rehabilitation beds and serves 29 percent of all Medicare patients, the analyst said. The IRF business makes 81 percent of the company's revenue, and Encompass managed to decrease its net debt/LTM EBITDA from 4.6 percent to 3.1 percent, said Rice.
The $58 price target is based on a valuation of 9.5 times Credit Suisse's 2019 EBITDA estimate and the stock is trading at 9.5 times the 2018 EBITDA estimate. Two main competitors are trading at 8.8 times and the broader peer average is 10.7 times, Rice said. Credit Suisse likes the stock because of its solid balance sheet, dividend and market leadership position, and sees it as a compelling name, Rice said.
The Price Action
Encompass Health was up about 2.36 percent near the end of Wednesday's trading session.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.